Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $-36.62M.
ENTERPRISE VALUE (EV)
$-36.62M
Kalaris Therapeutics Inc
Market Cap
$61.12M
Enterprise Value (EV)
$-36.62M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $61.12M | $-36.62M |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.11M | $39.83M |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.05M | $33.64M |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.98M | $56.31M |
| Fractyl Health, Inc. (GUTS)vs › | $59.89M | $73.49M |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.99M | $50.18M |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | $67.64M |
| RenovoRx, Inc. (RNXT)vs › | $64.20M | $54.98M |
Market Cap
$61.12M
Total Debt
$316000.00
Cash
$98.05M
Enterprise Value
$-36.62M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
